1.Association between hypertension and the risk of gallstone disease
Wenqian YU ; Linjun XIE ; Shiyi LI ; Yanmei LOU ; Guoheng JIANG ; Hongyu LI ; Zitong YAN ; Xuan BAI ; Jing LUO ; Chi ZHANG ; Guangcan LI ; Xuefeng SHAN ; Xin WANG
Journal of Clinical Hepatology 2024;40(6):1215-1225
Objective This article aims to investigate the association between hypertension and the risk of GSD by conducting a national multicenter study,a systematic review,and a meta-analysis.Methods The study was conducted in three stages.In the first stage,subjects were recruited for health examination in four hospitals in Chengdu,Tianjin,Beijing,and Chongqing,China,from 2015 to 2020,and the multivariate logistic regression analysis was used to investigate the association between hypertension and the risk of GSD in each center.In the second stage,Embase,PubMed,Wanfang Data,VIP,and CNKI databases were searched for related studies published up to May 2021,and a meta-analysis was conducted to further verify such association.In the third stage,the random effects model was used for pooled analysis of the results of the multicenter cross-sectional study and the findings of previous literature.Results A total of 633 948 participants were enrolled in the cross-sectional study,and the prevalence rate of GSD was 7.844%.The multivariate logistic regression analysis showed that hypertension was positively associated with the risk of GSD(P<0.05).Subgroup analysis showed that there was no significant difference in the association between hypertension and GSD between individuals with different sexes,ages,and subtypes of GSD.A total of 80 articles were included in the systematic review and the meta-analysis,and the results showed that the risk of GSD was increased by 1.022 times for every 10 mmHg increase in diastolic pressure and 1.014 times for every 10 mmHg increase in systolic pressure.Conclusion Hypertension significantly increases the risk of GSD,and the findings of this study will provide a basis for the etiology of GSD and the identification of high-risk groups.
2.MiR-375-3p enhanced radiosensitivity of colorectal cancer cells by inhibiting homologous recombination repair of DSBs
Changyong LI ; Meng JIA ; Qi WANG ; Linjun YAN ; Zhidong WANG ; Zhenhua QI
Chinese Journal of Radiological Medicine and Protection 2022;42(3):168-174
Objective:To investigate the effect of miR-375-3p on DNA damage repair and radioresistance of colorectal cancer cells.Methods:After overexpression of miR-375-3p in HCT116 and HT29, cell proliferation ability was detected by CCK-8 assay, clone formation ability was detected by clone formation assay, apoptosis was detected by Annexin V-FITC/PI double staining method and cell cycle distribution was detected by flow cytometry, and the formation of γ-H2AX foci were used to analyze homologous recombination (HR) repair efficiency. Bioinformatics was used to predict the downstream target genes of miR-375-3p in the HR repair pathway. A dual luciferase reporter gene assay was used to validate the regulation effect of miR-375-3p on Rad51 gene. The expression of miR-375-3p in HCT116 cells irradiated with 60Co γ-rays at 2 and 6 Gy was measured by RT-qPCR. The inhibition effect of miR-375-3p on the radiosensitivity of HCT116 cells was analyzed after irradiation with different doses of 0, 1, 2, 4 and 6 Gy. Results:Overexpression of miR-375-3p inhibited the proliferation and colony formation ability, induced G1 phase cycle arrest and cell apoptosis of colorectal cancer cells, enhanced DSBs formation, inhibited Rad51 expression, and significantly decreased HR repair efficiency ( t = 10.055, P < 0.05). Dual luciferase reporter gene assay demonstrated that miR-375-3p bound to Rad51 3′UTR region ( t = 5.013, P< 0.05). In addition, irradiation increased miR-375-3p expression, and inhibition of miR-375-3p expression reduced radiosensitivity of colorectal cancer cells ( t=6.460, 5.619, 10.150, P<0.05). Conclusions:miR-375-3p inhibited the homologous recombination repair efficiency of DSBs and enhanced the radiosensitivity of colorectal cancer cells.
3.Analysis of treatment for 360 critically ill pregnant and parturient women in intensive care unit
Jinxi YUE ; Qingqing HUANG ; Zongfang REN ; Yang YANG ; Yushan DUAN ; Yan CHEN ; Linjun WAN
Chinese Critical Care Medicine 2022;34(8):853-857
Objective:To analyze the clinical characteristics and outcomes of critically ill pregnant and parturient women in intensive care unit (ICU), and to provide clinical experience for the subspecialty construction of critical obstetrics.Methods:The clinical data of critically ill pregnant and parturient women admitted to the department of critical care medicine, the Second Affiliated Hospital of Kunming Medical University from January 2011 to December 2019 were collected. The main reasons for maternal transfer to ICU, the causes of maternal death, and organ support measures, etc. were summarized.Results:A total of 39 567 critically ill pregnant and parturient women were admitted to the department of obstetrics in our hospital, and 360 were transferred to ICU, with an average ICU transfer rate of 0.91%. Since 2016, the number of obstetric admissions, the number of ICU transfers and the ICU transfer rate had increased significantly. The average age of severe maternals admitted to ICU was (30.9±5.7) years old. The average acute physiology and chronic health evaluation Ⅱ(APACHEⅡ) score was 7 (4, 10). The average length of ICU stay was 1 (1, 2) day. The average ventilator duration was 9.0 (3.0, 17.5) hours. The main delivery mode of pregnant women in ICU was cesarean section (84.72%). Forty-eight patients (13.33%) underwent hysterectomy, of which 42 (87.5%) due to postpartum hemorrhage. The top 3 causes of ICU admission were severe postpartum hemorrhage [36.94% (133/360)], hypertensive disorders of pregnancy [21.67% (78/360)], pregnancy with cardiac disease [15.00% (54/360)]. The leading cause of postpartum hemorrhage in women transferred to ICU was placental abnormality [63.98% (103/161)], followed by uterine atony [28.57% (46/161)]. The average blood loss was (4 019±2 327) mL within 24 hours after delivery, and the number of women who underwent hysterectomy due to postpartum hemorrhage decreased year by year. During the study period, there were 2 maternal deaths, which were indirect obstetric deaths, 3 cases were discharged against-advice (expected death), including 1 indirect death and 2 direct obstetric death; the mortality in ICU was 1.39% (5/360).Conclusions:The most common reasons for pregnant and parturient women to be admitted to ICU were severe postpartum hemorrhage and hypertensive disorders of pregnancy. The leading cause of postpartum hemorrhage was placental problem. Indirect obstetric deaths exceeded direct obstetric deaths, mainly due to pregnancy complicated with cardiac disease and severe pneumonia. ICU has become an important battlefield for rescuing critically ill maternal and an important guarantee for reducing the maternal mortality.
4.Neoadjuvant Chemotherapy–Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study
Hongzhe SHI ; Wen ZHANG ; Xingang BI ; Dong WANG ; Zejun XIAO ; Youyan GUAN ; Kaopeng GUAN ; Jun TIAN ; Hongsong BAI ; Linjun HU ; Chuanzhen CAO ; Weixing JIANG ; Zhilong HU ; Jin ZHANG ; Yan CHEN ; Shan ZHENG ; Xiaoli FENG ; Changling LI ; Yexiong LI ; Jianhui MA ; Yueping LIU ; Aiping ZHOU ; Jianzhong SHOU
Cancer Research and Treatment 2021;53(4):1156-1165
Purpose:
Reduced quality of life after cystectomy has made bladder preservation a popular research topic for muscle-invasive bladder cancer (MIBC). Previous research has indicated significant tumor downstaging after neoadjuvant chemotherapy (NAC). However, maximal transurethral resection of bladder tumor (TURBT) was performed before NAC to define the pathology, impacting the real evaluation of NAC. This research aimed to assess real NAC efficacy without interference from TURBT and apply combined modality therapies guided by NAC efficacy.
Materials and Methods:
Patients with cT2-4aN0M0 MIBC were confirmed by cystoscopic biopsy and imaging. NAC efficacy was assessed by imaging, urine cytology, and cystoscopy with multidisciplinary team discussion. Definite responders (≤ T1) underwent TURBT plus concurrent chemoradiotherapy. Incomplete responders underwent radical cystectomy or partial cystectomy if feasible. The primary endpoint was the bladder preservation rate.
Results:
Fifty-nine patients were enrolled, and the median age was 63 years. Patients with cT3-4 accounted for 75%. The median number of NAC cycles was three. Definite responders were 52.5%. The complete response (CR) was 10.2%, and 59.3% of patients received bladder-sparing treatments. With a median follow-up of 44.6 months, the 3-year overall survival (OS) was 72.8%. Three-year OS and relapse-free survival were 88.4% and 60.0% in the bladder-sparing group but only 74.3% and 37.5% in the cystectomy group. The evaluations of preserved bladder function were satisfactory.
Conclusion
After stratifying MIBC patients by NAC efficacy, definite responders achieved a satisfactory bladder-sparing rate, prognosis, and bladder function. The CR rate reflected the real NAC efficacy for MIBC. This therapy is worth verifying through multicenter research.
5.A preliminary study on the effect of miRNA-181a on biological features of multiple myeloma cells
Wenhao ZHANG ; Linjun CHEN ; Zhichao LI ; Siguo HAO ; Rong TAO ; Xiaohui DENG ; Liyuan MA ; Jiangbo WAN ; Chuanxu LIU ; Yan ZHANG
Journal of Leukemia & Lymphoma 2017;26(8):452-456,460
Objective To explore the expression of miRNA-181a (miR-181a) in patients with multiple myeloma (MM) and its effect on biological features of MM cells. Methods CD138+cells of bone marrow from 25 MM patients and 10 patients with hematological non-malignancies were purified by using immunomagnetic separation, and the expression of miR-181a in CD138+cells and MM cell lines including RPMI 8226, H929 and U266 were detected by real-time quantitative PCR. The effects of down-regulation and up-regulation of miR-181a expression on the biological characteristics of MM cells were studied with miR-181a antagomir and agomir. Results Compared with patients with hematological non-malignant diseases, the expression of miR-181a in CD138+ cells was upregulated in MM patients. Compared with CD138+ cells in hematological non-malignancies, high expressions of miR-181a were observed in RPMI 8226 and U266 myeloma cell line, while low expressions of miR-181a were observed in H929 cells. Down-regulation of miR-181a with 100 nmol/L miR-181a antagomir could inhibit the proliferation of U266 cells at 24,48 and 72 h [(67.1 ± 3.3) %vs. (50.5 ± 4.1) %, (71.5 ± 3.6) % vs. (52.3 ± 2.2) %, (78.1 ± 5.4) % vs. (69.5 ± 4.3) %, P < 0.05 respectively], whereas up-regulation of miR-181a with 100 nmol/L miR-181a agomir could significantly promote the proliferation of H929 cells at 24 h and 48 h [(21.2 ± 2.4) %vs. (38.5 ± 3.6) %, ( 61.3 ± 5.4) %vs. (82.2 ±6.9)%, P<0.01 respectively]. Cell cycle analysis showed that miR-181a antagomir made U266 cell cycle arrest in the G0/G1 phase. Meanwhile, susceptibility test results indicated that the apoptosis of U266 cells induced by doxorubicin, paclitaxel and 5-fluorouracil was increased when the proliferation of miR-181a expression was down-regulated with miR-181a antagomir. In migration assay, the data showed that down-regulation of miR-181a with miR-181a antagomir could inhibit the migration of U266 cells, and the proportion of migrated cells in the experimental group (62 ± 10) %was lower than that in the control group (89 ± 12) %(P< 0.05), whereas up-regulation of miR-181a with miR-181a agomir could improve the migration of H929 cells, and the proportion of migrated cells in the experimental group (242 ± 9) % was higher than that in the control group (98 ± 8)%(P<0.01). Conclusions The high expression of miR-181a expressed highly by MM cells may promote the proliferation, migration and drug resistance of myeloma cells, indicating that miR-181a could be an important prognostic biomarker candidate, and the application of gene silencing may improve the prognosis of MM.
6.Effect of positive reduction of blood pressure in acute period on reperfusion of patients with acute ischemic stroke by intravenous thrombolysis
Hao MENG ; Linjun YANG ; Yan PU
Journal of Clinical Medicine in Practice 2017;21(17):31-34
Objective To investigate the effect of positive reduction of blood pressure on reperfusion of patients with acute ischemic stroke by intravenous thrombolysis.Methods A total of 96 acute ischemic stroke patients with intravenous thrombolysis of rt-PA and systolic blood pressure 150 to 185 mmHg selected and randomly divided into observation group and control group,48 cases in each group.The patients in the observation group received positive reduction of blood pressure in the acute phase,which indicated the systolic blood pressure was controlled at 140 to 150 mmHg and maintained at least 72 h in the beginning of 60 minutes.Patients in the control group received standard blood pressure according to the guidelines,which indicated systolic blood pressure control below 180 mmHg.The patients in both groups were given multi mode MRI examination before and 24 h,48 h and 72 h after intravenous thrombolysis.The levels of blood pressure,National Institute of Health stroke scale (NIHSS),blood flow reperfusion and recanalization of the two groups were recorded.The two groups were followed up for a period of three months.The survival status and the modified Rankin scale scores of the two groups were observed.Results Compared with the control group,the systolic blood pressure of 24,48 and 72 h in the observation group were lower than that of the control group,but there was no significant difference in diastolic blood pressure and NIHSS scores in the two groups (P > 0.05).There were no significant differences between the two groups in the rate of spontaneous intracerebral hemorrhage,survival rate,modified Rankin score (0 ~ 2),blood flow reperfusion rate and vascular recanalization rate (P > 0.05).Conclusion Acute venous thrombosis in the acute phase of reperfusion for acute ischemic stroke patients has no adverse effects on reperfusion and no increase of morbidity and death risk of patients,and intravenous thrombolysis to avoid systolic pressure rise can improve the prognosis of patients.
7.Effect of positive reduction of blood pressure in acute period on reperfusion of patients with acute ischemic stroke by intravenous thrombolysis
Hao MENG ; Linjun YANG ; Yan PU
Journal of Clinical Medicine in Practice 2017;21(17):31-34
Objective To investigate the effect of positive reduction of blood pressure on reperfusion of patients with acute ischemic stroke by intravenous thrombolysis.Methods A total of 96 acute ischemic stroke patients with intravenous thrombolysis of rt-PA and systolic blood pressure 150 to 185 mmHg selected and randomly divided into observation group and control group,48 cases in each group.The patients in the observation group received positive reduction of blood pressure in the acute phase,which indicated the systolic blood pressure was controlled at 140 to 150 mmHg and maintained at least 72 h in the beginning of 60 minutes.Patients in the control group received standard blood pressure according to the guidelines,which indicated systolic blood pressure control below 180 mmHg.The patients in both groups were given multi mode MRI examination before and 24 h,48 h and 72 h after intravenous thrombolysis.The levels of blood pressure,National Institute of Health stroke scale (NIHSS),blood flow reperfusion and recanalization of the two groups were recorded.The two groups were followed up for a period of three months.The survival status and the modified Rankin scale scores of the two groups were observed.Results Compared with the control group,the systolic blood pressure of 24,48 and 72 h in the observation group were lower than that of the control group,but there was no significant difference in diastolic blood pressure and NIHSS scores in the two groups (P > 0.05).There were no significant differences between the two groups in the rate of spontaneous intracerebral hemorrhage,survival rate,modified Rankin score (0 ~ 2),blood flow reperfusion rate and vascular recanalization rate (P > 0.05).Conclusion Acute venous thrombosis in the acute phase of reperfusion for acute ischemic stroke patients has no adverse effects on reperfusion and no increase of morbidity and death risk of patients,and intravenous thrombolysis to avoid systolic pressure rise can improve the prognosis of patients.
8.A multicenter randomized phase III trial of domestic product of rmhTNF in the treatment of non-small cell lung cancer.
Qinghua ZHOU ; Xi YAN ; Li REN ; Lu LI ; Meng QIU ; Yuqiong YANG ; Deyun LUO ; Wenxia HUANG ; Luming LIU ; Zhen CHEN ; Zhiqiang MENG ; Yajie WANG ; Qiang FU ; Yang XU ; Linjun YANG ; Mingzhong LI ; Enxiao LI ; Yi LI ; Yu YAO ; Xiangfu ZHANG ; Xing LIU ; Huishan LU ; Maohong ZHANG ; Xiuwen WANG ; Xuejun YU ; Fengzhan QIN ; Rongsheng ZHENG ; Yuqing CHEN ; Minghong BI
Chinese Journal of Lung Cancer 2003;6(4):264-267
BACKGROUNDTo evaluate and compare the effects and toxicity of the domestic product of recombinant mutant human tumor necrosis factor (rmhTNF) combined with chemotherapy and chemotherapy alone in the treatment of patients with non-small cell lung cancer (NSCLC).
METHODSTwo hundred patients with NSCLC in multicenter were randomly devided into trial group (150 cases) and control group (50 cases). Chemotherapy with CAP regimen was given to the patients. Meanwhile, rmhTNF injection of 4×10⁶U/m² was also given from the 1st to 7th days, the 11th to 17th days on the chemotherapy cycle in the trial group. The control patients received chemotherapy alone. Twenty-one days were as a cycle, 2 cycles were given to each patient. The chemotherapeutic effects and toxicity were observed and compared between the two groups after the therapy.
RESULTSof the 200 patients, 5 cases in the trial group and 3 cases in the control group were out of the trial because of economy. The other 192 cases (145 cases in the trial group and 47 cases in the control group) could be analyzed and evaluated the clinical effects and toxicity. The response rate of chemotherapy was 46.90% (68/145) in the trial group and 17.02% (8/47) in the control group respectively ( P =0.001). The KPS scores was 86.02±9.74 in the trial group, and 80.14±9.10 in the control group ( P =0.025). No significant difference of degree III+IV toxicity was observed between the two groups ( P > 0.05). The side effects related to rmhTNF included slight fever, cold-like symptoms, pain and red and swelling in the injection site. All of them were mild and didn't need any treatment and disappeared after the therapy. There were no severe abnormality of liver and kidney function and ECG in both groups.
CONCLUSIONSThe results demonstrate that the effects of domestic rmhTNF combined with chemotherapy are remarkably higher than that of chemotherapy alone in the treatment of NSCLC. rmhTNF can increase the sensitivity to chemotherapy and improve the quality of life of the patients with slight toxicity. Hence rmhTNF is worth expanding clinical use.

Result Analysis
Print
Save
E-mail